Medicinal Bioconvergence Research Center
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Aug 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Sep 1, 2027The maintenance fee for Method for screening an agent preventing or treating cancer using glycyl-tRNA synthetase and cadherin (US 9,274,113) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Polypeptide having chemokine activity and uses thereof (US 10,646,547) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 21, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,139,394 | Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase In force · USPTO record | In force | USPTO record | |
| US 9,435,807 | Use of leucyl tRNA synthetase In force · USPTO record | In force | USPTO record | |
| US 10,130,611 | Use of Benzo-Heterocycle Derivatives for Preventing and Treating Cancer or for Inhibiting Cancer Metastasis In force · High confidence | In force | High confidence | |
| US 9,274,113 | Method for screening an agent preventing or treating cancer using glycyl-tRNA synthetase and cadherin In force · USPTO record | In force | USPTO record | |
| US 10,258,674 | Nanoparticles comprising aminoacyl tRNA synthetase and anticancer composition comprising same In force · USPTO record | In force | USPTO record | |
| US 10,646,547 | Polypeptide having chemokine activity and uses thereof In force · USPTO record | In force | USPTO record | |
| US 11,173,192 | Anti-RNA virus composition comprising EPRS protein or fragment thereof In force · USPTO record | In force | USPTO record | |
| US 11,518,817 | Monoclonal antibody specifically binding to MRS In force · USPTO record | In force | USPTO record | |
| US 11,649,231 | NOVEL COMPOUND AS mTOR INHIBITOR AND USE THEREOF In force · High confidence | In force | High confidence | |
| US 11,561,222 | Method for Diagnosis of Bile Duct Cancer Using Methionyl-tRNA Synthetase in Bile Duct Cell In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 8 patents in force now held by others · 8 lapsed for an unpaid fee · 4 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 9 no status recorded